{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T19:55:46Z","timestamp":1774727746658,"version":"3.50.1"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:p>This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD).<\/jats:p>","DOI":"10.1001\/jamapsychiatry.2023.3979","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T15:33:24Z","timestamp":1698248004000},"page":"1187","source":"Crossref","is-referenced-by-count":8,"title":["Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression\u2014Advantage Ketamine?"],"prefix":"10.1001","volume":"80","author":[{"given":"Sanjay J.","family":"Mathew","sequence":"first","affiliation":[{"name":"Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas"},{"name":"Mental Health Care Line, Michael E. DeBakey VA Medical Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish K.","family":"Jha","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas"},{"name":"O\u2019Donnell Brain Institute, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham and Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"yvp230032r1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ijnp\/pyab088","article-title":"Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT).","volume":"25","author":"Ekstrand","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"issue":"25","key":"yvp230032r2","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression.","volume":"388","author":"Anand","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"yvp230032r3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jamapsychiatry.2023.0562","article-title":"Ketamine vs electroconvulsive therapy for major depressive episode: a systematic review and meta-analysis.","volume":"80","author":"Menon","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"yvp230032r4","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","article-title":"Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis.","volume":"79","author":"Rhee","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"yvp230032r5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1176\/appi.ajp.21111086","article-title":"An update on community ketamine practices.","volume":"179","author":"O\u2019Brien","year":"2022","journal-title":"Am J Psychiatry"},{"issue":"8","key":"yvp230032r6","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"yvp230032r7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1176\/appi.ajp.20220216","article-title":"A novel, brief, fully automated intervention to extend the antidepressant effect of a single ketamine infusion: a randomized clinical trial.","volume":"179","author":"Price","year":"2022","journal-title":"Am J Psychiatry"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2811309\/jamapsychiatry_mathew_2023_vp_230032_1700673889.10898.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T16:03:50Z","timestamp":1701878630000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2811309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":7,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.3979","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}